BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Liver cancer AND uPA AND Treatment
76 results:

  • 1. Circulating tumor DNA in unresectable pancreatic cancer is a strong predictor of first-line treatment efficacy: The KRASCIPANC prospective study.
    Evrard C; Ingrand P; Rochelle T; Martel M; Tachon G; Flores N; Randrian V; Ferru A; Haineaux PA; Goujon JM; Karayan-Tapon L; Tougeron D
    Dig Liver Dis; 2023 Nov; 55(11):1562-1572. PubMed ID: 37308396
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Involvement of matrix metalloproteinase 1 and urokinase-type plasminogen activator in the PKCα-p38 MAPK pathway-mediated progression of human liver cancer cells.
    Ye JC; Hsieh YS; Chen PN; Liu JY; Hsieh YH
    Drug Dev Res; 2023 Jun; 84(4):767-776. PubMed ID: 37005497
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Evaluation of marketing authorization and clinical implementation of ulipristal acetate for uterine fibroids.
    Middelkoop MA; de Lange ME; Clark TJ; Mol BWJ; Bet PM; Huirne JAF; Hehenkamp WJK
    Hum Reprod; 2022 May; 37(5):884-894. PubMed ID: 35143669
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Phase III long-term study to evaluate the efficacy and safety of ulipristal acetate in Japanese patients with uterine fibroids.
    Osuga Y; Nakano Y; Yamauchi Y; Murakawa H
    J Obstet Gynaecol Res; 2021 Sep; 47(9):3269-3278. PubMed ID: 34109697
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Discovery of Novel Pyrimidine-Based Capsid Assembly Modulators as Potent Anti-HBV Agents.
    Kim W; Kang JA; Park M; Jeong PH; Kim YJ; Cho Y; Park SG; Kim YC
    J Med Chem; 2021 May; 64(9):5500-5518. PubMed ID: 33887912
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Management of women with uterine fibroids in reproductive center: retrospective analysis of clinical and reproductive outcomes.
    Miriello D; Galanti F; Meneghini C; Fabiani C; Dal Lago A; Schiavi MC; Rago R
    Minerva Obstet Gynecol; 2022 Apr; 74(2):130-136. PubMed ID: 33876897
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Use of Ulipristal Acetate and Risk of liver Disease: A Nationwide Cohort Study.
    Yoon EL; Yuk JS
    J Clin Endocrinol Metab; 2021 May; 106(6):1773-1782. PubMed ID: 33567071
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway.
    Conde de la Rosa L; Garcia-Ruiz C; Vallejo C; Baulies A; Nuñez S; Monte MJ; Marin JJG; Baila-Rueda L; Cenarro A; Civeira F; Fuster J; Garcia-Valdecasas JC; Ferrer J; Karin M; Ribas V; Fernandez-Checa JC
    J Hepatol; 2021 Jun; 74(6):1429-1441. PubMed ID: 33515644
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Medical Therapy for Fibroids: What Next for Ulipristal Acetate?
    Ekanem E; Talaulikar V
    Adv Ther; 2021 Jan; 38(1):137-148. PubMed ID: 33201387
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. A Notch-Dependent Inflammatory Feedback Circuit between Macrophages and cancer Cells Regulates Pancreatic cancer Metastasis.
    Geng Y; Fan J; Chen L; Zhang C; Qu C; Qian L; Chen K; Meng Z; Chen Z; Wang P
    Cancer Res; 2021 Jan; 81(1):64-76. PubMed ID: 33172931
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. A multi-centre, randomized, non-inferiority trial to compare ulipristal with standard surgical treatment in women with symptomatic uterine fibroids: Protocol of the MYOMEX-2 trial.
    Middelkoop MA; Huirne JAF; van der Weide MCJ; Bosmans JE; Hehenkamp WJK;
    Eur J Obstet Gynecol Reprod Biol; 2021 Jan; 256():63-69. PubMed ID: 33171419
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis.
    Gatti M; Poluzzi E; De Ponti F; Raschi E
    Drug Saf; 2020 Dec; 43(12):1277-1285. PubMed ID: 32748236
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Suspension of ulipristal acetate for uterine fibroids during ongoing EMA's review of liver injury risk: Unfortunate timing during the Covid-19 pandemic!
    Rozenberg S; Revercez P; Fastrez M; Vandromme J; Bucella D
    Eur J Obstet Gynecol Reprod Biol; 2020 Sep; 252():300-302. PubMed ID: 32650189
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib.
    Giannelli G; Santoro A; Kelley RK; Gane E; Paradis V; Cleverly A; Smith C; Estrem ST; Man M; Wang S; Lahn MM; Raymond E; Benhadji KA; Faivre S
    PLoS One; 2020; 15(3):e0222259. PubMed ID: 32210440
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Beneficial effect of fluoxetine on anti-tumor progression on hepatocellular carcinoma and non-small cell lung cancer bearing animal model.
    Hsu LC; Tu HF; Hsu FT; Yueh PF; Chiang IT
    Biomed Pharmacother; 2020 Jun; 126():110054. PubMed ID: 32145588
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. What does non-eligibility for myoma surgery mean in the context of sequential prescription of ulipristal acetate?
    Pourcelot AG; Capmas P; Laberge P; Fernandez H
    J Gynecol Obstet Hum Reprod; 2020 Apr; 49(4):101688. PubMed ID: 31972353
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Elevated levels of serum urokinase plasminogen activator predict poor prognosis in hepatocellular carcinoma after resection.
    Tsai MC; Yen YH; Chang KC; Hung CH; Chen CH; Lin MT; Hu TH
    BMC Cancer; 2019 Dec; 19(1):1169. PubMed ID: 31791275
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. EC313-a tissue selective SPRM reduces the growth and proliferation of uterine fibroids in a human uterine fibroid tissue xenograft model.
    Nair HB; Santhamma B; Dileep KV; Binkley P; Acosta K; Zhang KYJ; Schenken R; Nickisch K
    Sci Rep; 2019 Nov; 9(1):17279. PubMed ID: 31754172
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. liver function, tolerability and satisfaction during treatment with ulipristal acetate in women with fibroids: a single center experience.
    Del Forno S; Degli Esposti E; Salucci P; Leonardi D; Iodice R; Arena A; Raimondo D; Paradisi R; Seracchioli R
    Gynecol Endocrinol; 2020 May; 36(5):445-447. PubMed ID: 31646908
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. TIMP3 expression associates with prognosis in colorectal cancer and its novel arylsulfonamide inducer, MPT0B390, inhibits tumor growth, metastasis and angiogenesis.
    Huang HL; Liu YM; Sung TY; Huang TC; Cheng YW; Liou JP; Pan SL
    Theranostics; 2019; 9(22):6676-6689. PubMed ID: 31588243
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 4.